Status:
WITHDRAWN
Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)
Lead Sponsor:
Tambi Jarmi
Conditions:
Ischemia Reperfusion Injury
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this research is to test an investigational drug called Adipose Mesenchymal Stem Cells (aMSCs) for the treatment of ischemia re-perfusion injury (IRI) in patients that have had a kidney...
Eligibility Criteria
Inclusion
- Male or female kidney transplant candidates age 18 and above.
- Patient is receiving kidney allograft from deceased donor with KDPI\>85%.
- Ability of subject to give appropriate consent.
- Females of childbearing potential with agreement to use birth control for six months post-transplant.
- Approved by the Mayo Clinic Transplant Selection Committee.
- Signed Authorization for Donation of Anatomical Gifts on file.
Exclusion
- Positive pregnancy test at the time of the kidney offer is called for the potential recipient.
- Kidney transplant potential recipients with active malignancy (except none melanoma skin malignancies).
- Patients with previous history of solid organ transplant (Heart, Lung, Intestine, Kidney and/or Pancreas).
- Patients with previous history of bone marrow transplant.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04388761
Start Date
September 1 2020
End Date
February 1 2024
Last Update
October 18 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.